2018—2023年苏州市成人HPV疫苗疑似预防接种异常反应监测结果分析  

Surveillance of Adverse Events Following Immunization with Human Papilloma Virus Vaccines among Adults in Suzhou from 2018 to 2023

作　　者：高金玲 栾琳[1] 徐娟 巢婷婷 朱丹枫 刘娜[1,2] Gao Jinling;Luan Lin;Xu Juan;Chao Tingting;Zhu Danfeng;Liu Na(Suzhou Center for Disease Control and Prevention,Suzhou,Jiangsu,215000,China;不详)

机构地区：[1]苏州市疾病预防控制中心,江苏苏州215000 [2]中国疾病预防控制中心,北京100050

出　　处：《中国初级卫生保健》2024年第11期89-93,共5页Chinese Primary Health Care

基　　金：苏州市姑苏卫生人才计划(2022年第127号);苏州市姑苏卫生人才计划人才科研项目(GSWS2021055)。

摘　　要：目的:对2018—2023年苏州市成人(≥18周岁)人乳头瘤病毒(Human papilloma vinus, HPV)疫苗接种后报告的疑似预防接种异常反应(Adverse events following ummunization, AEFI)监测数据进行分析,为多种HPV疫苗上市后的安全性监测提供数据支撑。方法:通过中国疾病预防控制信息系统AEFI监测系统,筛选2018—2023年苏州市2价HPV疫苗(HPV2)、4价HPV疫苗(HPV4)和9价HPV疫苗(HPV9) AEFI个案数据,通过江苏省预防接种综合服务管理信息系统成人模块,收集2018—2023年苏州市多种HPV疫苗的接种资料,分析AEFI个案的基本分布、分类情况等。结果:2018—2023年苏州市共报告成人HPV疫苗AEFI个案215例,报告发生率为13.79/10万剂,其中一般反应207例,占97.28%。HPV2、HPV4和HPV9 AEFI的一般反应、异常反应和偶合症报告发生率比较,差异均无统计学意义(P>0.05)。从AEFI基本情况来看,35~39岁(25.12%)、第2季度(30.70%)、接种剂次为第1剂次(42.33%)报告的AEFI人数最多。HPV疫苗AEFI一般反应的临床表现以发热(57例,3.65/10万剂)、局部红肿(97例,6.21/10万剂)和局部硬结(54例,3.46/10万剂)为主。成人HPV疫苗AEFI主要发生在接种后1 d以内,HPV2、HPV4和HPV9发生AEFI的时间间隔为≤1 d的病例占比分别为82.35%、89.09%和79.35%。结论:2018—2023年苏州市成人HPV疫苗安全性良好,各医疗机构需保持报告敏感性。OBJECTIVE To evaluate the surveillance data of adverse events following immunization(AEFI)of human papilloma virus(HPV)vaccines among adults(≥18 years old)in Suzhou from 2018 to 2023,and to provide data support for the safety monitor⁃ing of multiple HPV vaccines.METHODS The AEFI caused by the 2-valent vaccines,4-valent vaccines,and 9-valent vaccines?in Suzhou from 2018 to 2023 were screened through the Chinese Disease Control of immunization information management system.The vaccination data in Suzhou from 2018 to 2023 were collected by the adult module of Jiangsu province vaccination integrated service management information system for the basic distribution and classification of AEFI.RESULTS The overall of AEFI reported after HPV vaccination was 215 among adults in Suzhou from 2018 to 2023,with a reported incidence of 13.76/105 doses,of which 207 cases(97.28%)were general reactions.There was no significant difference in the reported incidence of AEFI for the 2-valent vac⁃cines,4-valent vaccines,and 9-valent vaccines.According to the basic situation of AEFI,the majority of AEFI were aged between 35 and 39(25.12%),the most were reported in the second quarter(30.70%),and the most were reported in the first dose(42.33%).The main clinical manifestations were fever(57 cases),local redness(97 cases)and local induration(54 cases).AEFI of the 2-valent vaccines,4-valent vaccines,and 9-valent vaccines occurred within 1 day after vaccination in 82.35%,89.09%and 79.35%,respec⁃tively.CONCLUSION The safety of HPV vaccine among adults in Suzhou from 2018 to 2023 was high,and all medical institutions still maintain the sensitivity of reporting.

关 键 词：人乳头瘤病毒疫苗 疑似预防接种异常反应 监测 安全性 

分 类 号：R186[医药卫生—流行病学]